Revcovi FDA Approval History
FDA Approved: Yes (First approved October 5, 2018)
Brand name: Revcovi
Generic name: elapegademase-lvlr
Dosage form: Injection
Company: Leadiant Biosciences, Inc.
Treatment for: Adenosine Deaminase Severe Combined Immune
Deficiency (ADA-SCID)
Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID).
Development timeline for Revcovi
| Date | Article |
|---|---|
| Oct 5, 2018 | Approval FDA Approves Revcovi (elapegademase-lvlr) for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
